MDRNA Sells Manufacturing Business to Par Pharmaceuticals to Hone RNAi Focus | GenomeWeb

MDRNA this week said that Par Pharmaceuticals has agreed to purchase its manufacturing facilities in Hauppauge, NY, as well as its abbreviated new drug application for generic calcitonin-salmon nasal spray, for an undisclosed amount.

The agreement, which eliminates all of MDRNA's non-RNAi expenses, "represents the final step in our plan to create a company solely focused in the research and development of RNAi-based therapeutics," Michael French, president and CEO of MDRNA, said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.